相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
John Nemunaitis et al.
MOLECULAR THERAPY (2010)
Initial Testing of the Replication Competent Seneca Valley Virus (NTX-010) by the Pediatric Preclinical Testing Program
Christopher L. Morton et al.
PEDIATRIC BLOOD & CANCER (2010)
A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients
J-L Li et al.
GENE THERAPY (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC
Qiuwei Pan et al.
ACTA ONCOLOGICA (2008)
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents
Toshiyoshi Fujiwara et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
Differential effects of combined Ad5-Δ24RGD and radiation therapy in In vitro versus In vivo models of malignant glioma
Martine L. M. Lamfers et al.
CLINICAL CANCER RESEARCH (2007)
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter
Marta M. Alonso et al.
CANCER RESEARCH (2007)
An oncolytic adenovirus redirected with a tumor-specific T-Cell receptor
Zsolt Sebestyen et al.
CANCER RESEARCH (2007)
Seneca valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
P. Seshidhar Reddy et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
J. Nemunaitis et al.
CANCER GENE THERAPY (2007)
Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus
Jin Cheng et al.
MOLECULAR THERAPY (2007)
Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL
Qiuwei Pan et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2007)
A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms
Ivan Delgado-Enciso et al.
JOURNAL OF GENE MEDICINE (2007)
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models
Martin E. Wohlfahrt et al.
CANCER RESEARCH (2007)
Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells
Ilya V. Ulasov et al.
JOURNAL OF NEUROSURGERY (2007)
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma
Ilya V. Ulasov et al.
HUMAN GENE THERAPY (2007)
Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy
Kerry D. Fisher et al.
JOURNAL OF DRUG TARGETING (2007)
Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter
Toshiyoshi Fujiwara et al.
CURRENT CANCER DRUG TARGETS (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
Yu-An Zhang et al.
CANCER RESEARCH (2006)
Small RNAs and non-small cell lung cancer
Alex W. Tong
CURRENT MOLECULAR MEDICINE (2006)
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
HL Kaufman et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee
JH Tai et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus
NK Green et al.
GENE THERAPY (2004)
A Cox-2 promoter-based replication-selective adenoviral vector to target the Cox-2-expressing human bladder cancer cells
T Shirakawa et al.
CLINICAL CANCER RESEARCH (2004)
Telomerase-specific replication-selective virotherapy for human cancer
T Kawashima et al.
CLINICAL CANCER RESEARCH (2004)
Functions and mechanisms of action of the adenovirus E3 proteins
DL Lichtenstein et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2004)
Ad-mTERT-Δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner
E Kim et al.
HUMAN GENE THERAPY (2003)
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
J Nemunaitis et al.
CANCER GENE THERAPY (2003)
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer
O Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus
K Doronin et al.
VIROLOGY (2003)
Oncolytic herpes simplex virus vectors for cancer virotherapy
S Varghese et al.
CANCER GENE THERAPY (2002)
Selectively replicating viral vectors
J Nemunaitis et al.
CANCER GENE THERAPY (2002)
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
J Gulley et al.
PROSTATE (2002)
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses
PJ Cozzi et al.
PROSTATE (2002)
Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells
MJ Savontaus et al.
GENE THERAPY (2002)
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
PA Vasey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer
T Endo et al.
CANCER GENE THERAPY (2002)
Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation
SV Blank et al.
HUMAN GENE THERAPY (2002)
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma
SM Chung et al.
GENE THERAPY (2002)
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study
V Papanastassiou et al.
GENE THERAPY (2002)
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
N Habib et al.
CANCER GENE THERAPY (2002)
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3)
P Shankar et al.
VACCINE (2001)
Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
M Ramachandra et al.
NATURE BIOTECHNOLOGY (2001)
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial
T Reid et al.
GENE THERAPY (2001)
Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells
TM Timiryasova et al.
JOURNAL OF GENE MEDICINE (2001)
Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen
A Schütz et al.
CANCER GENE THERAPY (2001)
Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer
TJ Jorgensen et al.
NEOPLASIA (2001)
A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes
JF Carew et al.
MOLECULAR THERAPY (2001)
Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor α2 chain
K Kawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer
JJ Bennett et al.
ANNALS OF SURGERY (2001)
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
T Todo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
J Nemunaitis et al.
GENE THERAPY (2001)
Telomerase and cancer
JW Shay et al.
HUMAN MOLECULAR GENETICS (2001)
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma
RJ Wong et al.
HUMAN GENE THERAPY (2001)
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial
S Mulvihlll et al.
GENE THERAPY (2001)
Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model
ES Lambright et al.
MOLECULAR THERAPY (2000)
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
C Heise et al.
NATURE MEDICINE (2000)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
FR Khuri et al.
NATURE MEDICINE (2000)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation
MA Spear et al.
CANCER GENE THERAPY (2000)
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
K Doronin et al.
JOURNAL OF VIROLOGY (2000)
Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors
T Todo et al.
CANCER GENE THERAPY (2000)
Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8+ cytotoxic T lymphocytes
C Berger et al.
JOURNAL OF VIROLOGY (2000)
Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
S Mukherjee et al.
CANCER GENE THERAPY (2000)
Conditionally replicating herpes vectors for cancer therapy
RL Martuza
JOURNAL OF CLINICAL INVESTIGATION (2000)
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
JN Parker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
J Fueyo et al.
ONCOGENE (2000)
Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
T Kurihara et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
